Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.57 - $0.88 $6,198 - $9,570
-10,875 Reduced 2.81%
376,750 $327,000
Q1 2023

May 12, 2023

SELL
$0.61 - $1.03 $19,398 - $32,754
-31,800 Reduced 7.58%
387,625 $271,000
Q4 2022

Feb 13, 2023

SELL
$0.62 - $1.21 $6,782 - $13,237
-10,940 Reduced 2.54%
419,425 $343,000
Q3 2022

Nov 14, 2022

BUY
$1.05 - $2.1 $65,038 - $130,076
61,941 Added 16.81%
430,365 $448,000
Q2 2022

Aug 15, 2022

BUY
$1.42 - $3.15 $57,396 - $127,323
40,420 Added 12.32%
368,424 $604,000
Q1 2022

May 13, 2022

BUY
$2.65 - $5.08 $101,720 - $194,995
38,385 Added 13.25%
328,004 $964,000
Q4 2021

Feb 14, 2022

BUY
$4.73 - $7.9 $200,514 - $334,896
42,392 Added 17.15%
289,619 $1.38 Million
Q3 2021

Nov 15, 2021

BUY
$5.16 - $7.98 $450,106 - $696,095
87,230 Added 54.52%
247,227 $1.87 Million
Q2 2021

Aug 13, 2021

BUY
$6.45 - $9.09 $373,932 - $526,983
57,974 Added 56.82%
159,997 $1.19 Million
Q1 2021

May 14, 2021

BUY
$7.25 - $13.82 $447,129 - $852,320
61,673 Added 152.85%
102,023 $796,000
Q4 2020

Feb 12, 2021

BUY
$6.87 - $10.48 $122,286 - $186,544
17,800 Added 78.94%
40,350 $373,000
Q3 2020

Nov 16, 2020

BUY
$5.06 - $7.23 $35,673 - $50,971
7,050 Added 45.48%
22,550 $156,000
Q2 2020

Aug 14, 2020

BUY
$1.57 - $6.56 $24,335 - $101,680
15,500 New
15,500 $102,000
Q3 2018

Nov 13, 2018

SELL
$8.92 - $17.83 $342,447 - $684,511
-38,391 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$12.83 - $17.41 $492,556 - $668,387
38,391 New
38,391 $627,000

Others Institutions Holding SURF

About Surface Oncology, Inc.


  • Ticker SURF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,034,000
  • Description
  • Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...
More about SURF
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.